FDA Approves Augtyro (repotrectinib) for People with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
On Nov. 16, 2023, the U.S. Food and Drug Administration (FDA) approved Augtyro (repotrectinib) for people living with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a ROS1 gene mutation. The approval was based on results from [...]